Federated Hermes, Inc. Karuna Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$98.9 - $132.37 $90.6 Million - $121 Million	-916,519 Reduced 99.88%	1,083 $137,000
Q4 2021 Feb 14, 2022	BUY	$110.64 - $159.4 $34,409 - $49,573	311 Added 0.03%	917,602 $120 Million
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $1.49 Million - $1.85 Million	-14,693 Reduced 1.58%	917,291 $112 Million
Q2 2021 Aug 16, 2021	SELL	$107.45 - $135.95 $6.27 Million - $7.93 Million	-58,322 Reduced 5.89%	931,984 $106 Million
Q1 2021 May 13, 2021	BUY	$95.46 - $133.08 $44.3 Million - $61.8 Million	464,313 Added 88.27%	990,306 $119 Million
Q4 2020 Feb 12, 2021	BUY	$75.23 - $109.23 $14 Million - $20.3 Million	185,872 Added 54.65%	525,993 $53.4 Million
Q3 2020 Nov 12, 2020	SELL	$71.31 - $109.74 $843,240 - $1.3 Million	-11,825 Reduced 3.36%	340,121 $26.3 Million
Q2 2020 Aug 13, 2020	BUY	$62.14 - $117.21 $3.45 Million - $6.51 Million	55,535 Added 18.74%	351,946 $39.2 Million
Q1 2020 May 13, 2020	BUY	$60.41 - $115.92 $17.9 Million - $34.4 Million	296,409 Added 0.0%	296,411 $21.3 Million
Q4 2019 Feb 14, 2020	BUY	$11.44 - $123.99 $22 - $247	2 New	2 $1,000

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.